Robert Damoiseaux

Professor & Director

UCLA Health

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Robert Damoiseaux is a Professor and Director at UCLA Health in the United States. His research focuses on antiviral activity, high throughput screening for caspase inhibitors, and cellular signaling in beta cells. Additionally, he investigates synaptic risk genes related to neurodegenerative diseases and the optimization of models for drug screening in respiratory conditions. His recent publications highlight advancements in drug discovery and mechanisms of disease related to various cellular phenomena.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (7)

UNITED STATES

View details

Mikael Elofsson

Umea University

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Robert Damoiseaux

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Open Source Repurposing Reveals Broad-Spectrum Antiviral Activity of Diphenylureas

An activation-based high throughput screen identifies caspase-10 inhibitors

FXYD2 marks and regulates maturity of β cells via ion channel-mediated signal transduction

Key Connectomes and Synaptic-Compartment-Specific Risk Genes Drive Pathological α-Synuclein Spreading

Optimization of a micro-scale air–liquid-interface model of human proximal airway epithelium for moderate throughput drug screening for SARS-CoV-2

βIV spectrin abundancy, cellular distribution and sensitivity to AKT/GSK3 regulation in schizophrenia

N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma

Chemoproteomics Identifies State-Dependent and Proteoform-Selective Caspase-2 Inhibitors

Expression of Concern: Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma

FLECS technology for high-throughput screening of hypercontractile cellular phenotypes in fibrosis: A function-first approach to anti-fibrotic drug discovery

A High-Content Screen Identifies Drugs That Restrict Tumor Cell Extravasation across the Endothelial Barrier

Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication

Classes of Drugs that Mitigate Radiation Syndromes

Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2

DUSP7 regulates the activity of ERK2 to promote proper chromosome alignment during cell division

Massively scaled-up testing for SARS-CoV-2 RNA via next-generation sequencing of pooled and barcoded nasal and saliva samples

PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates

SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition

Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease

Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition

Collaborators (7)

Consuelo Walss‐Bass

Arun Sharma

Gabriel Oland

Agenor Limon

Tsui-Fen Chou

Samuel Kharpatin

Mikael Elofsson

Make your next move.